OM Quote, Financials, Valuation and Earnings

Integra Lifesciences Holdings has a net margin of -86.66% compared to Outset Medical's net margin of -6.61%. Outset Medical's return on equity of -140.06% beat Integra Lifesciences Holdings's return on equity of -1.88%.

Outset Medical has a consensus price target of $26.50, signalling upside risk potential of 29.52%. On the other hand Integra Lifesciences Holdings has an analysts' consensus of $16.13 which suggests that it could grow by 30.15%. Given that Integra Lifesciences Holdings has higher upside potential than Outset Medical, analysts believe Integra Lifesciences Holdings is more attractive than Outset Medical.

Outset Medical has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Integra Lifesciences Holdings has a beta of 1.164, suggesting its more volatile than the S&P 500 by 16.396%.

Outset Medical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Integra Lifesciences Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Outset Medical pays -- of its earnings as a dividend. Integra Lifesciences Holdings pays out -- of its earnings as a dividend.

Outset Medical quarterly revenues are $29.8M, which are smaller than Integra Lifesciences Holdings quarterly revenues of $382.7M. Outset Medical's net income of -$25.8M is lower than Integra Lifesciences Holdings's net income of -$25.3M. Notably, Outset Medical's price-to-earnings ratio is -- while Integra Lifesciences Holdings's PE ratio is 70.14x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Outset Medical is 0.77x versus 0.59x for Integra Lifesciences Holdings. Usually stocks with elevated PS ratios are considered overvalued.

Pro-Dex has a net margin of -86.66% compared to Outset Medical's net margin of 18.81%. Outset Medical's return on equity of -140.06% beat Pro-Dex's return on equity of 29.31%.

Outset Medical has a consensus price target of $26.50, signalling upside risk potential of 29.52%. On the other hand Pro-Dex has an analysts' consensus of $56.00 which suggests that it could grow by 38.03%. Given that Pro-Dex has higher upside potential than Outset Medical, analysts believe Pro-Dex is more attractive than Outset Medical.

Outset Medical has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Pro-Dex has a beta of 0.169, suggesting its less volatile than the S&P 500 by 83.086%.

Outset Medical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pro-Dex offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Outset Medical pays -- of its earnings as a dividend. Pro-Dex pays out -- of its earnings as a dividend.

Outset Medical quarterly revenues are $29.8M, which are larger than Pro-Dex quarterly revenues of $17.4M. Outset Medical's net income of -$25.8M is lower than Pro-Dex's net income of $3.3M. Notably, Outset Medical's price-to-earnings ratio is -- while Pro-Dex's PE ratio is 14.54x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Outset Medical is 0.77x versus 2.13x for Pro-Dex. Usually stocks with elevated PS ratios are considered overvalued.

Insulet has a net margin of -86.66% compared to Outset Medical's net margin of 6.22%. Outset Medical's return on equity of -140.06% beat Insulet's return on equity of 36.9%.

Outset Medical has a consensus price target of $26.50, signalling upside risk potential of 29.52%. On the other hand Insulet has an analysts' consensus of $336.00 which suggests that it could grow by 9.59%. Given that Outset Medical has higher upside potential than Insulet, analysts believe Outset Medical is more attractive than Insulet.

Outset Medical has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Insulet has a beta of 1.375, suggesting its more volatile than the S&P 500 by 37.475%.

Outset Medical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Insulet offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Outset Medical pays -- of its earnings as a dividend. Insulet pays out -- of its earnings as a dividend.

Outset Medical quarterly revenues are $29.8M, which are smaller than Insulet quarterly revenues of $569M. Outset Medical's net income of -$25.8M is lower than Insulet's net income of $35.4M. Notably, Outset Medical's price-to-earnings ratio is -- while Insulet's PE ratio is 55.14x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Outset Medical is 0.77x versus 10.32x for Insulet. Usually stocks with elevated PS ratios are considered overvalued.

Stryker has a net margin of -86.66% compared to Outset Medical's net margin of 11.15%. Outset Medical's return on equity of -140.06% beat Stryker's return on equity of 14.2%.

Outset Medical has a consensus price target of $26.50, signalling upside risk potential of 29.52%. On the other hand Stryker has an analysts' consensus of $421.46 which suggests that it could grow by 11.76%. Given that Outset Medical has higher upside potential than Stryker, analysts believe Outset Medical is more attractive than Stryker.

Outset Medical has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Stryker has a beta of 0.914, suggesting its less volatile than the S&P 500 by 8.615%.

Outset Medical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Stryker offers a yield of 0.87% to investors and pays a quarterly dividend of $0.84 per share. Outset Medical pays -- of its earnings as a dividend. Stryker pays out 40.73% of its earnings as a dividend. Stryker's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Outset Medical quarterly revenues are $29.8M, which are smaller than Stryker quarterly revenues of $5.9B. Outset Medical's net income of -$25.8M is lower than Stryker's net income of $654M. Notably, Outset Medical's price-to-earnings ratio is -- while Stryker's PE ratio is 50.96x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Outset Medical is 0.77x versus 6.27x for Stryker. Usually stocks with elevated PS ratios are considered overvalued.